Cormorant Asset Management, LP is an SEC-registered investment adviser based in Boston, MA that reports managing 1 hedge fund on Form ADV. It reports $3.8 billion in regulatory assets under management. Its private funds, of all types, hold $3.8 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +11.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +36.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $3.8 billionForm ADV Item 5.F
- Gross assets of private funds
- $3.8 billionAll private fund types, Form ADV
- Hedge funds managed
- 17 private funds in total
- Employees
- 12Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 167820
- Latest Form ADV
- 05/27/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +13.2% | +14.8% |
| Q1 2026 | -1.9% | -4.6% |
| Q4 2025 | +33.0% | +2.4% |
| Q3 2025 | +9.1% | +7.8% |
| Q2 2025 | +7.1% | +10.4% |
| Q1 2025 | -24.3% | -4.5% |
| Q4 2024 | -5.4% | +2.1% |
| Q3 2024 | +10.4% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 60 share positions ($1,489,258,905) reported by Cormorant Asset Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Parabilis Medicines Inc10.01%
- Praxis Precision Medicines I9.78%
- Rapport Therapeutics Inc5.54%
- Edgewise Therapeutics Inc5.07%
- Bridgebio Oncology Therapeut4.92%
- Erasca Inc4.92%
- Blossomhill Therapeutics Inc4.52%
- Adlai Nortye LTD4.27%
- Dianthus Therapeutics Inc2.96%
- Abivax SA2.83%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Parabilis Medicines Inc | $149,038,111 | 10.01% | 4,615,612 | Unchanged |
| Praxis Precision Medicines I | $145,615,000 | 9.78% | 500,000 | -21.88% |
| Rapport Therapeutics Inc | $82,572,706 | 5.54% | 2,457,521 | -7.53% |
| Edgewise Therapeutics Inc | $75,516,000 | 5.07% | 1,860,000 | -25.90% |
| Bridgebio Oncology Therapeut | $73,302,235 | 4.92% | 17,878,594 | Unchanged |
| Erasca Inc | $73,300,000 | 4.92% | 5,000,000 | -16.67% |
| Blossomhill Therapeutics Inc | $67,365,594 | 4.52% | 3,614,034 | New |
| Adlai Nortye LTD | $63,651,664 | 4.27% | 3,978,229 | Unchanged |
| Dianthus Therapeutics Inc | $44,025,000 | 2.96% | 500,000 | -33.33% |
| Abivax SA | $42,083,500 | 2.83% | 425,000 | -37.04% |
| Bright Minds Biosciences Inc | $39,856,000 | 2.68% | 800,000 | -11.11% |
| Electra Therapeutics Inc | $37,862,249 | 2.54% | 3,365,533 | New |
| Moonlake Immunotherapeutics | $33,408,566 | 2.24% | 2,855,433 | -10.92% |
| Oruka Therapeutics Inc | $33,316,000 | 2.24% | 400,000 | -25.00% |
| Attovia Therapeutics Inc | $30,660,285 | 2.06% | 1,788,815 | New |
| Faeth Therapeutics Inc | $30,579,917 | 2.05% | 1,028,242 | Unchanged |
| Latigo Biotherapeutics Inc | $30,322,858 | 2.04% | 1,815,740 | New |
| Agomab Therapeutics NV | $27,365,363 | 1.84% | 2,465,348 | Unchanged |
| Opus Genetics Inc | $26,620,000 | 1.79% | 5,500,000 | New |
| Climb Bio Inc | $24,155,820 | 1.62% | 2,106,000 | Unchanged |
| Freenome Inc | $22,538,754 | 1.51% | 1,431,032 | New |
| MBX Biosciences Inc | $21,982,500 | 1.48% | 375,000 | -31.82% |
| Biohaven LTD | $20,158,500 | 1.35% | 1,510,000 | -42.15% |
| Adarx Pharmaceuticals Inc | $19,200,176 | 1.29% | 962,898 | New |
| Eyepoint Inc | $18,802,500 | 1.26% | 5,750,000 | -17.86% |
| Tango Therapeutics Inc | $17,465,000 | 1.17% | 700,000 | -46.15% |
| Damora Therapeutics Inc Com SHS | $17,024,000 | 1.14% | 800,000 | New |
| Bridgebio Pharma Inc | $16,450,000 | 1.10% | 250,000 | -54.55% |
| Cue Biopharma Inc | $16,176,123 | 1.09% | 625,285 | New |
| Corbus Pharmaceuticals Hldgs | $15,992,702 | 1.07% | 2,344,971 | Unchanged |
| Bioage Labs Inc | $15,885,889 | 1.07% | 2,240,605 | -6.27% |
| Alumis Inc | $15,334,250 | 1.03% | 2,075,000 | -36.85% |
| Olema Pharmaceuticals Inc | $15,120,000 | 1.02% | 1,750,000 | -18.60% |
| Pharvaris N V | $14,274,000 | 0.96% | 450,000 | -40.00% |
| Helix Acquisition Corp III | $13,779,450 | 0.93% | 1,297,500 | Unchanged |
| Spyre Therapeutics Inc | $11,128,750 | 0.75% | 125,000 | -44.44% |
| Definium Therapeutics Inc | $10,466,500 | 0.70% | 275,000 | -31.25% |
| Aclaris Therapeutics Inc | $9,205,000 | 0.62% | 1,750,000 | New |
| Amylyx Pharmaceuticals Inc | $8,730,000 | 0.59% | 300,000 | +50.00% |
| Cabaletta Bio Inc | $8,640,000 | 0.58% | 4,500,000 | -10.00% |
| Inhibrx Biosciences Inc | $5,004,000 | 0.34% | 50,000 | New |
| Kailera Therapeutics Inc | $4,568,000 | 0.31% | 400,000 | -27.27% |
| Jade Biosciences Inc | $4,215,000 | 0.28% | 300,000 | New |
| Ibio Inc | $4,212,600 | 0.28% | 3,570,000 | Unchanged |
| Tarsus Pharmaceuticals Inc | $3,930,500 | 0.26% | 50,000 | -50.00% |
| Roivant Sciences LTD | $3,657,000 | 0.25% | 100,000 | -78.95% |
| Enliven Therapeutics Inc | $3,438,000 | 0.23% | 75,000 | -50.00% |
| Ascendis Pharma A/s | $3,417,450 | 0.23% | 15,000 | -70.00% |
| Odyssey Therapeutics Inc | $2,777,500 | 0.19% | 125,000 | -28.57% |
| Newamsterdam Pharma Company | $2,432,000 | 0.16% | 100,000 | -80.00% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 13 new positions, 3 sold out, 1 increased, 36 reduced and 10 unchanged.
Number of positions (a count, not dollars)
- New positions13
- Increased1
- Unchanged10
- Reduced36
- Sold out3
New positions
| Stock | Value | Shares |
|---|---|---|
| Blossomhill Therapeutics Inc | $67,365,594 | 3,614,034 |
| Electra Therapeutics Inc | $37,862,249 | 3,365,533 |
| Attovia Therapeutics Inc | $30,660,285 | 1,788,815 |
| Latigo Biotherapeutics Inc | $30,322,858 | 1,815,740 |
| Opus Genetics Inc | $26,620,000 | 5,500,000 |
| Freenome Inc | $22,538,754 | 1,431,032 |
| Adarx Pharmaceuticals Inc | $19,200,176 | 962,898 |
| Damora Therapeutics Inc Com SHS | $17,024,000 | 800,000 |
| Cue Biopharma Inc | $16,176,123 | 625,285 |
| Aclaris Therapeutics Inc | $9,205,000 | 1,750,000 |
| Inhibrx Biosciences Inc | $5,004,000 | 50,000 |
| Jade Biosciences Inc | $4,215,000 | 300,000 |
| Braveheart Bio Inc | $1,414,000 | 70,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Damora Therapeutics Inc | $26,010,000 | 1,000,000 |
| Crinetics Pharmaceuticals In | $4,677,500 | 125,000 |
| Altimmune Inc | $3,800,000 | 1,250,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | +100,000 | +50.00% | $8,730,000 | 300,000 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Praxis Precision Medicines I | -140,000 | -21.88% | $145,615,000 | 500,000 |
| Edgewise Therapeutics Inc | -650,000 | -25.90% | $75,516,000 | 1,860,000 |
| Abivax SA | -250,000 | -37.04% | $42,083,500 | 425,000 |
| Dianthus Therapeutics Inc | -250,000 | -33.33% | $44,025,000 | 500,000 |
| Bridgebio Pharma Inc | -300,000 | -54.55% | $16,450,000 | 250,000 |
| Tango Therapeutics Inc | -600,000 | -46.15% | $17,465,000 | 700,000 |
| Biohaven LTD | -1,100,000 | -42.15% | $20,158,500 | 1,510,000 |
| Erasca Inc | -1,000,000 | -16.67% | $73,300,000 | 5,000,000 |
| Roivant Sciences LTD | -375,000 | -78.95% | $3,657,000 | 100,000 |
| Oruka Therapeutics Inc | -133,340 | -25.00% | $33,316,000 | 400,000 |
| MBX Biosciences Inc | -175,000 | -31.82% | $21,982,500 | 375,000 |
| Newamsterdam Pharma Company | -400,000 | -80.00% | $2,432,000 | 100,000 |
| Pharvaris N V | -300,000 | -40.00% | $14,274,000 | 450,000 |
| Alumis Inc | -1,210,596 | -36.85% | $15,334,250 | 2,075,000 |
| Spyre Therapeutics Inc | -100,000 | -44.44% | $11,128,750 | 125,000 |
| Ascendis Pharma A/s | -35,000 | -70.00% | $3,417,450 | 15,000 |
| Rapport Therapeutics Inc | -200,000 | -7.53% | $82,572,706 | 2,457,521 |
| Insmed Inc | -55,000 | -73.33% | $2,282,800 | 20,000 |
| Bright Minds Biosciences Inc | -100,000 | -11.11% | $39,856,000 | 800,000 |
| Definium Therapeutics Inc | -125,000 | -31.25% | $10,466,500 | 275,000 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. | 13G amendment | 5.12% | 2,457,521 | Nov 16, 2026 | SEC.gov ↗ |
| Opus Genetics, Inc. | 13G | 6.61% | 5,500,000 | Nov 16, 2026 | SEC.gov ↗ |
| EyePoint, Inc. | 13G amendment | 6.67% | 5,750,000 | Nov 16, 2026 | SEC.gov ↗ |
| Electra Therapeutics, Inc. | 13G | 5.36% | 3,365,533 | Nov 16, 2026 | SEC.gov ↗ |
| Bright Minds Biosciences Inc. | 13G amendment | 8.11% | 800,000 | Nov 16, 2026 | SEC.gov ↗ |
| Cue Biopharma, Inc. | 13G | 9.99% | 791,377 | Nov 16, 2026 | SEC.gov ↗ |
| Cabaletta Bio, Inc. | 13G amendment | 2.65% | 4,500,000 | Nov 16, 2026 | SEC.gov ↗ |
| BioAge Labs, Inc. | 13G amendment | 4.88% | 2,240,605 | Nov 16, 2026 | SEC.gov ↗ |
| Corbus Pharmaceuticals Holdings, Inc. | 13G amendment | 7.76% | 1,500,000 | Nov 2, 2026 | SEC.gov ↗ |
| Rallybio Corp | 13G amendment | 0% | 0 | Aug 14, 2026 | SEC.gov ↗ |
| Quince Therapeutics, Inc. | 13G | 9.99% | 108,029 | Aug 14, 2026 | SEC.gov ↗ |
| MoonLake Immunotherapeutics | 13G amendment | 4.35% | 3,205,433 | Aug 14, 2026 | SEC.gov ↗ |
| iBio, Inc. | 13G amendment | 9.99% | 5,117,481 | Aug 14, 2026 | SEC.gov ↗ |
| Adlai Nortye Ltd. | 13G amendment | 6.77% | 3,978,229 | Aug 14, 2026 | SEC.gov ↗ |
| BlossomHill Therapeutics, Inc. | 13D | 11.79% | 3,614,034 | Aug 13, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 24, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 21 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (6)
As reported in the adviser's Form ADV filed May 22, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures